MALAT1 Knockdown Protects from Bronchial/Tracheal Smooth Muscle Cell Injury Via Regulation of Microrna-133A/Ryanodine Receptor 2 Axis
Total Page:16
File Type:pdf, Size:1020Kb
J Biosci (2021)46:28 Ó Indian Academy of Sciences DOI: 10.1007/s12038-021-00149-3 (0123456789().,-volV)(0123456789().,-volV) MALAT1 knockdown protects from bronchial/tracheal smooth muscle cell injury via regulation of microRNA-133a/ryanodine receptor 2 axis 1 2 MINGZHU YANG and LI WANG * 1Department of Pediatric Internal Medicine, Xian Yang Central Hospital, Xianyang 712000, People’s Republic of China 2Department of Laboratory Medicine, Affiliated Hospital of Shaanxi University of Chinese Medicine, Xianyang 712000, People’s Republic of China *Corresponding author (Email, [email protected]) MS received 9 December 2019; accepted 12 February 2021 Asthma has significant impacts on living quality particularly in children. Long noncoding RNA (lncRNA) MALAT1 plays a crucial role in neonatal respiratory diseases. Meanwhile, MALAT1 knockdown could induce viability and attenuate apoptosis of airway-related cells. However, the role of MALAT1 in neonatal asthma, asthma-related cell, and its possible mechanism is unclear. This study aims to investigate MALAT1 level in asthma and to identify the effects of MALAT1 on bronchial/tracheal smooth muscle cells (B/TSMCs). Newborn asthma modeling rat was constructed by introducing ovalbumin (OVA). MALAT1 levels in tissues or B/TSMCs were determined by RT-qPCR. Exogenous changes of MALAT1, RyR2 or miR-133a in B/TSMCs were fulfilled by cell transfection; cell apoptosis was measured by using Cell Death Detection ELISA kit and Hochest33342; IL-6, TNF-a and IL-1b level was detected by using corresponding ELISA kit; ryanodine receptor 2 (RyR2) mRNA and miR-133a level was determined by RT-qPCR; cleaved caspase-3 (c-caspase-3) and RyR2 expression was detected by Western blot; luciferase reporter assay was performed to confirm the target regulation of miR-133a on RyR2. We found that MALAT1 was significantly upregulated in tracheal tissues of newborn asthma modeling rats. In MALAT1-silenced or -overexpressed B/TSMCs, we found a synchronous change of cell apoptosis, inflammatory factor secretion (IL-6, TNF-a, and IL-1b) or RyR2 level, but a reverse change of miR-133a level with MALAT1. Besides, MALAT1 induced B/TSMCs apoptosis and inflammation increase could be partially reversed when RyR2 was silenced or when miR-133a was overex- pressed. The luciferase reporter assay confirmed that RyR2 is a direct target gene of miR-133a in B/TSMCs. Finally, we conclude that MALAT1 knockdown could protect from B/TSMCs injury via regulating miR-133a/ RyR2 axis. Keywords. Asthma; apoptosis; inflammation response; MALAT1; microRNA-133a; ryanodine receptor 2 1. Introduction asthma is increasing year by year. The United States reported that the incidence of asthma and wheezing in Asthma is one of the most common chronic inflam- children is as high as 9. 4% (about 7 million), and the matory diseases, which is mainly consisting of recur- number of asthma-related deaths is 7, 000 per year rent airway obstruction, bronchial hyper- (Dinakar and Chipps 2017). The pathogenesis of responsiveness, and airway inflammatory cell infiltra- asthma refers to numerous genetic factors and envi- tion. The symptoms of asthma generally includes ronmental factors like allergens (Dutmer et al. 2016; recurrent wheezing, chest tightness, cough, as well as Gagro 2011). For a long time, asthma has significant sensation and shortness of breath (Han et al. 2016; Hsu impacts on living quality particularly in children, in et al. 2016). Nowadays the incidence of childhood some way due to the higher incidence of allergies in http://www.ias.ac.in/jbiosci 28 Page 2 of 12 Mingzhu Yang and Li Wang them (Chang 2012). For children, asthma is generally properties of mesenchymal stem cells by inducing characterized by its heterogeneity in terms of etiology, vascular endothelial growth factor (VEGF) (Li et al. degree of inflammatory response, airway obstruction as 2017). Currently, the role of MALAT1 in pediatric well as pulmonary function (Gagro 2011). Therefore, asthma or airway smooth muscle cells is still unknown. timely diagnosis and treatment are essential to prevent MicroRNAs (miRNAs) are short noncoding inflammatory response, airway remodeling and pul- endogenous RNAs with a length of 18–25 nucleotides, monary function decline. Although there are some which regulate gene-expression by binding and effective strategies for asthma prevention and treatment inhibiting mRNA post-transcriptionally (Lu and in children, the risk factors and specific mechanisms of Rothenberg 2018; Simonson and Das 2015). Evidences pediatric asthma are still unclear. have suggested that lncRNAs function as endogenous Long noncoding RNA (LncRNA) belongs to non- miRNA sponges by binding to miRNAs and then coding RNAs with a length about 200 nucleotides or causing malfunction of various pathological and more (Li et al. 2016), which plays important roles in a physiological processes (Ahmed et al. 2016). Previ- wide range of biological processes thus has relevance ously, studies have revealed that miRNAs like MiR- with multiple human diseases for example cancer and 3162–3p (Fang et al. 2016)and microRNA-19b (Ye cardiovascular disease (Zhang et al. 2018). In recent et al. 2017)could regulate the functions of airway in years, accumulated studies have demonstrated that asthma animal models. Besides, microRNA-1 down- lncRNA is also associated with the pathogenesis of regulation could regulate smooth muscle hypertrophy asthma (Omran et al. 2013; Zhu et al. 2018). For during asthmatic disease (Chen et al. 2006). Micro- instance, Austin PJ et al. identified that lnRNA plas- RNA-155 knockout mice exhibited rapid airway macytoma variant translocation (PVT1) is a novel remodeling and collagen deposition in smooth muscle regulator of the asthmatic phenotype in human airway cells (Nicolas et al. 2009). A discovery that micro- smooth muscle (Austin et al. 2017). The lncRNA RNA-133a downregulation-mediated ras homolog metastasis-associated lung adenocarcinoma transcript 1 gene family member A (RhoA) increase could regulate (MALAT1) has been reported to implicate in tumor bronchial smooth muscle (BSM) contraction (Chiba progression (Cheng et al. 2018a, b; Orlandi et al. and Misawa 2010), hints that miRNA-133a may 2019), liver damage (Sookoian et al. 2018), and implicate in smooth muscle function in asthmatics, osteoarthritis (Zhang et al. 2019), while rarely in cross- which also aroused our interest. talk of respiratory disease. The discovery that In the present study, newborn asthma modeling rat MALAT1 knockdown could induce the viability and was successfully constructed by introducing ovalbumin attenuate the apoptosis of airway related cells, made (OVA). Then, we discovered that lncRNA MALAT1 MALAT1 to be a hopeful therapeutic target of neonatal was significantly upregulated in tracheal tissues of respiratory distress syndrome (NRDS) (Juan et al. newborn asthma modeling rats. In MALAT1-silenced 2018;Liet al. 2018a, b). Additionally, in asthma, air- or -overexpressed bronchial/tracheal smooth muscle way remodeling may coexist with airway inflamma- cells (B/TSMCs), we found a synchronous change of tion, causing the occurrence and persistence of chronic cell apoptosis rate and inflammatory response with inflammation due to airway smooth muscle cell MALAT1 levels. With the help of bioinformatics pre- inflammation and proliferative hypertrophy (B Andrew dictions, we confirmed by experiments that MALAT1 2008). Studies have revealed that some lncRNAs could induced B/TSMCs apoptosis and inflammatory regulate proliferation or inflammatory response of air- response may be partially fulfilled via its regulation on way smooth muscle cells during the development of miR-133a/RyR2 axis. Our findings identified the asthma, such as PVT1 (Austin et al. 2017) and adverse effects of MALAT1 on B/TSMCs, an impor- BCYRN1 (Zhang et al. 2016). It has been also reported tant cell line for asthma research. that MALAT1 can regulate the occurrence and devel- opment of diseases by participating in a variety of non- cancer cell proliferation, apoptosis, and inflammatory 2. Materials and methods reactions (Li et al. 2018a, b). For example, the release of pro-inflammatory cytokine and apoptosis of human 2.1 Animals and neonatal rat asthma modeling coronary artery endothelial cells were markedly ele- vated when MALAT1 was overexpressed (Li et al. Specific pathogen free (SPF) male Wistar rats (weigh- 2018a, b). Besides, MALAT1 could also promote ing 50±5 g at the beginning of sensitization) were proliferation, angiogenesis, and immunosuppressive purchased from Shanghai Laboratory Animal Research MALAT1 knockdown protects from B/TSMCs injury by miR 133a/RyR2 axis Page 3 of 12 28 Center (Shanghai, China). After adaptive feeding with 100 U/mL penicillin (Sigma Aldrich) at 37°C with 5% aseptic operation in SPF animal room (room tempera- CO2. ture: 25 ± 3°C; relative humidity: 40–60%; daily artificial lighting: 12 h), rats were randomly divided into control group and ovalbumin (OVA) group with 8 2.4 Cell transfection in each. For OVA group, rats were sensitized with 1 mg OVA (Grade II; Sigma-Aldrich, St. Louis, MO, USA) The siRNAs targeting MALAT1 (siMALAT1–1, and 100 mg aluminum hydroxide (Al(OH)3; Aladdin siMALAT1–2, siMALAT1–3) and its negative control Industrial Corporation, Shanghai, China) in 1 mL siRNA (siMALAT1-NC) were synthesized by Gene- saline by intraperitoneal injection on the 1st and 8th Pharma (Shanghai, China). Sequences of these siRNAs days (Ablimit et al. 2013; Cheng et al. 2018a, b); were as follows: siMALAT1–1, sense: 50-GAT CCA starting on the 15th day, rats were challenged with TAA TCG GTT TCA AGG-30, antisense: 50-TTG AAA inhaled OVA aerosol (1% w/v solution diluted in CCG ATT ATG GAT CAT-30; siMALAT1–2, sense: 50- saline; Grade V; Sigma-Aldrich) generated by a neb- GGC AAU GUU UUA CAC UAU UTT-30, antisense: ulizer for 30 min each time and repeated every other 50-AAU A GU GUA AAA CAU UGC CTA-30; day for 6 days. For the control group, rats were siMALAT1–3, sense: 50-GAG GUG UAA AGG GAU received treatments in the same way; however, they UUA UTT-30, antisense: 50-AUA AAU CCC UUU were intraperitoneally injected with 1 mL saline fol- ACA CCU CTT-30; si-MALAT1-NC, sense: 50-UUC lowed by inhalation of saline aerosol.